Shilpa Medicare Limited (NSE:SHILPAMED)

Market Cap	79.39B
Revenue (ttm)	12.86B
Net Income (ttm)	782.93M
Shares Out	n/a
EPS (ttm)	8.04
PE Ratio	101.40
Forward PE	32.15
Dividend	n/a
Ex-Dividend Date	n/a

Volume	310,698
Average Volume	583,947
Open	914.95
Previous Close	898.70
Day's Range	902.00 - 924.90
52-Week Range	496.45 - 959.50
Beta	0.24
RSI	75.02
Earnings Date	May 23, 2025

About Shilpa Medicare

Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, recombinant albumin in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatini...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 1,007
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SHILPAMED

Financial Performance

In 2024, Shilpa Medicare's revenue was 12.86 billion, an increase of 11.56% compared to the previous year's 11.53 billion. Earnings were 782.93 million, an increase of 145.63%.